Journal of International Oncology ›› 2024, Vol. 51 ›› Issue (8): 487-492.doi: 10.3760/cma.j.cn371439-20240318-00081
• Original Articles • Previous Articles Next Articles
Ni Guoying, Huang Qian, Liang Hongxiang, Yang Zhiyong, Ding Yingli()
Received:
2024-03-18
Revised:
2024-06-25
Online:
2024-08-08
Published:
2024-09-24
Contact:
Ding Yingli,Email:386937117@qq.com
Supported by:
Ni Guoying, Huang Qian, Liang Hongxiang, Yang Zhiyong, Ding Yingli. Analysis of changes in serum miR-499 and miR-362 levels and their relationship with prognosis in advanced NSCLC patients[J]. Journal of International Oncology, 2024, 51(8): 487-492.
"
临床特征 | 例数 | miR-499 | t值 | P值 | miR-362 | t值 | P值 |
---|---|---|---|---|---|---|---|
年龄(岁) | |||||||
<50 | 39 | 0.34±0.09 | 0.26 | 0.514 | 1.12±0.26 | 0.80 | 0.513 |
≥50 | 64 | 0.33±0.08 | 1.13±0.28 | ||||
性别 | |||||||
男 | 67 | 0.33±0.08 | 0.76 | 0.312 | 1.13±0.27 | 0.83 | 0.269 |
女 | 36 | 0.33±0.09 | 1.13±0.28 | ||||
分化程度 | |||||||
低分化 | 40 | 0.23±0.06 | 11.12 | <0.001 | 1.52±0.33 | 16.35 | <0.001 |
中高分化 | 63 | 0.35±0.08 | 1.11±0.26 | ||||
TNM分期 | |||||||
ⅢB | 48 | 0.34±0.09 | 13.64 | 0.002 | 1.12±0.27 | 8.73 | 0.010 |
Ⅳ | 55 | 0.24±0.06 | 1.45±0.31 | ||||
淋巴结转移 | |||||||
有 | 35 | 0.22±0.06 | 10.02 | 0.003 | 1.50±0.31 | 9.65 | 0.004 |
无 | 68 | 0.35±0.09 | 1.13±0.28 |
[1] |
Mithoowani H, Febbraro M. Non-small-cell lung cancer in 2022: a review for general practitioners in oncology[J]. Curr Oncol, 2022, 29(3): 1828-1839. DOI: 10.3390/curroncol29030150.
pmid: 35323350 |
[2] | 罗宏, 殷红, 胡广越, 等. 血清炎性标志物对非小细胞肺癌免疫治疗的预测价值[J]. 国际肿瘤学杂志, 2022, 49(3): 177-180. DOI: 10.3760/cma.j.cn371439-20211115-00030. |
[3] |
Crawford BM, Wang HN, Stolarchuk C, et al. Plasmonic nanobiosensors for detection of microRNA cancer biomarkers in clinical samples[J]. Analyst, 2020, 145(13): 4587-4594. DOI: 10.1039/d0an00193g.
pmid: 32436503 |
[4] | Nouri R, Ghorbian S. Association of single nucleotide polymorphism in hsa-miR-499 and hsa-miR-196a2 with the risk of prostate cancer[J]. Int Urol Nephrol, 2019, 51(5): 811-816. DOI: 10.1007/s11255-019-02099-0. |
[5] | 王泽洲, 张扬, 莫淼, 等. 大型单中心医院登记的7753例肺癌手术患者 生存报告: 基于第8版国际肺癌TNM分期标准[J]. 中国癌症杂志, 2020, 30(5): 321-327. DOI: 10.19401/j.cnki.1007-3639.2020.05.001. |
[6] | 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华肿瘤杂志, 2021, 43(6): 591-621. DOI: 10.3760/cma.j.cn112152-20210207-00118. |
[7] |
Suster DI, Mino-Kenudson M. Molecular pathology of primary non-small cell lung cancer[J]. Arch Med Res, 2020, 51(8): 784-798. DOI: 10.1016/j.arcmed.2020.08.004.
pmid: 32873398 |
[8] | Muthusamy B, Patil PD, Pennell NA. Perioperative systemic therapy for resectable non-small cell lung cancer[J]. J Natl Compr Canc Netw, 2022, 20(8): 953-961. DOI: 10.6004/jnccn.2022.7021. |
[9] | Tarighati E, Keivan H, Mahani H. A review of prognostic and predictive biomarkers in breast cancer[J]. Clin Exp Med, 2023, 23(1): 1-16. DOI: 10.1007/s10238-021-00781-1. |
[10] | 柯孔亮, 王金秋, 楼婷婷, 等. miRNA-455-5p对人结肠癌HT-29细胞株PIK3R1基因靶向调控作用的研究[J]. 浙江医学, 2020, 42(7): 650-655, 659. DOI: 10.12056/j.issn.1006-2785.2020.42.7.2019-2406. |
[11] |
Yazdani M, Beiki Z, Jahanian A. RNA secondary structured logic gates for profiling the microRNA cancer biomarkers[J]. IET Nanobiotechnol, 2020, 14(3): 181-190. DOI: 10.1049/iet-nbt.2019.0150.
pmid: 32338625 |
[12] |
Wardana T, Chasanah SN, Oktriani R, et al. Circulation microRNA expression profiles in patients with complete responses to chemoradiotherapy in nasopharyngeal carcinoma[J]. Noncoding RNA Res, 2022, 7(4): 233-241. DOI: 10.1016/j.ncrna.2022.09.005.
pmid: 36203524 |
[13] | 穆丽君, 管冰, 田娟华, 等. 肿瘤抑制因子microRNA-218对前列腺癌细胞恶性进展及肿瘤干细胞特性的调控作用[J]. 现代泌尿外科杂志, 2023, 28(2): 161-165. DOI: 10.3969/j.issn.1009-8291.2023.02.018. |
[14] |
Zhen Y, Liu J, Huang YJ, et al. MiR-133b inhibits cell growth, migration, and invasion by targeting MMP9 in non-small cell lung cancer[J]. Oncol Res, 2017, 25(7): 1109-1116. DOI: 10.3727/096504016X14800889609439.
pmid: 27938481 |
[15] | 李宝华, 戈海泽, 刘树业. miR-499在肝癌发生和发展中的作用机制研究[J]. 检验医学与临床, 2020, 17(8): 1012-1016. DOI: 10.3969/j.issn.1672-9455.2020.08.002. |
[16] | 罗丹. miR-362在非小细胞肺癌转移中的作用及分子机制[D]. 北京: 北京交通大学, 2019. |
[17] | Shi YK, Zang QL, Li GX, et al. Increased expression of microRNA-301a in nonsmall-cell lung cancer and its clinical significance[J]. J Cancer Res Ther, 2016, 12(2): 693-698. DOI: 10.4103/0973-1482.146130. |
[18] | Luo D, Zhang Z, Zhang Z, et al. Aberrant expression of miR-362 promotes lung cancer metastasis through downregulation of Sema3A[J]. J Immunol Res, 2018, 2018: 1687097. DOI: 10.1155/2018/1687097. |
[19] | 郝艳萍, 王光. 非小细胞肺癌患者血浆miR-499与miR-23a表达及其检测意义[J]. 临床肺科杂志, 2018, 23(2): 199-202. DOI: 10.3969/j.issn.1009-6663.2018.02.002. |
[20] |
Hong MJ, Choi YY, Jang JA, et al. Association between genetic variants in pre-microRNAs and survival of early-stage NSCLC[J]. J Thorac Oncol, 2013, 8(6): 703-710. DOI: 10.1097/JTO.0b013e318288dc0a.
pmid: 23470291 |
[21] | Liu C, Gao W, Shi Y, et al. Association between miR-146a rs2910164, miR-196a2 rs11614913, and miR-499 rs3746444 polymorphisms and the risk of esophageal carcinoma: a case-control study[J]. Cancer Med, 2022, 11(21): 3949-3959. DOI: 10.1002/cam4.4729. |
[22] |
Wang A, Wang J. E2F1-induced overexpression of long noncoding RNA SBF2-AS1 promotes non-small-cell lung cancer metastasis through regulating miR-362-3p/GRB2 axis[J]. DNA Cell Biol, 2020, 39(7): 1290-1298. DOI: 10.1089/dna.2020.5426.
pmid: 32364763 |
[23] | 高玉梅, 冯兴梅, 侯妍妍, 等. 微小RNA-499-5p靶向CYLD对肿瘤细胞增殖和侵袭的影响[J]. 中华实验外杂志, 2023, 40(12): 2566-2569. DOI: 10.3760/cma.j.cn421213-20230520-01158. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||